6/26/2025

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of Wall Street expectations, leading to a significant negative market reaction. Management attributed the subdued performance to factors including slower-than-anticipated uptake for newly launched products and specific regional pressures, such as a decline in ex-U.S. cystic fibrosis (CF) revenues due to market dynamics in Russia. CEO Reshma Kewalramani acknowledged, “Russia reve

Source: Yahoo

6/26/2025

Introduction The Delhi High Court has recently delivered two judgments underscoring how the procedural failures by the patent and trademark offices can unjustly prejudice rights. In Vertex...

Source: Finnhub

6/26/2025

In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500®Index benchmark by 95 basis points.

Source: SeekingAlpha

6/26/2025

Source: SeekingAlpha

6/25/2025

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

Source: Yahoo

6/24/2025

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880). Zimislecel is an investigational stem cell-derived, fully differentiated islet cell therapy […]

Source: Yahoo

6/24/2025

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

6/23/2025

The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.

Source: Yahoo

6/23/2025

BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein

Source: Yahoo

6/22/2025

The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with this event.

Source: SeekingAlpha

6/22/2025

Source: SeekingAlpha

6/21/2025

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.

Source: SeekingAlpha

6/20/2025

BOSTON, June 20, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American

Source: Yahoo

6/20/2025

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.

Source: Yahoo

6/20/2025

Presenter SpeechSusie Lisa Thanks for your patience. Good evening, everyone. My name is Susie Lisa, and I'm the Senior Vice President of Investor Relations for Vertex Pharmaceuticals. Thank you so...

Source: Finnhub

6/20/2025

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic […]

Source: Yahoo

6/20/2025

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

6/19/2025

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Source: Yahoo

6/19/2025

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

Source: Yahoo

6/19/2025

A decade after its IPO, Shopify still has the qualities that allowed it to deliver significantly above average returns. Despite recent issues, Vertex Pharmaceuticals' innovative lineup and pipeline should lead to strong performances.

Source: Yahoo